North America Lyophilized Injectable Market Forecast to 2028

North America Lyophilized Injectable Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type of Packaging (Single-Use Vials, Point-of-Care Reconstitution, and Specialty Packaging), Type of Delivery (Prefilled Diluent Syringes, Single-Step Devices, Proprietary Reconstitution Devices, and Multi-Step Devices), Indication (Metabolic and Oncology Conditions, Infectious Diseases, Autoimmune Diseases, and Others), and End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others)

Report Code : BMIRE00027594 | Region : North America | Industry : Pharmaceuticals | Published Date : 05/Dec/2022

The North America lyophilized injectable market is expected to grow from US$ 1,145.21 million in 2022 to US$ 1,612.66 million by 2028. It is estimated to grow at a CAGR of 5.9% from 2022 to 2028.

Increasing Demand for Biologics

The supply of numerous biologics in a liquid form is not possible. Pharmaceutical organizations may also have concerns that the pharmacodynamic and pharmacokinetic properties of certain biologics in a liquid stable format may diminish over time. The supply of biologics and other drugs is done in a lyophilized or powder form requiring reconstitution at the point of delivery, which is the only feasible pathway for the product's commercial launch. A significant boom has been witnessed in the contract manufacturing of biologics. This can be attributed to difficulties in the production of large-scale biologics in-house. There is a need to scale up the production once novel technologies get approved—for instance, the manufacturing of CAR-T therapy. With more biological products and biosimilars entering the market, the competition within the biopharmaceutical sector is becoming fierce. Biologics manufacturers strive to reduce manufacturing costs, deliver high-quality drugs, improve process efficiency, and accelerate market entry. CMOs can adapt as per requirement, help in process innovation, and improve operational efficiency. As the pharmaceutical industry is shifting from large-scale production to more niche and targeted therapies (personalized medicine), the demand for flexible operational capabilities, production scales, and multiple-product operations is offering significant advantages to CMOs. Moreover, many companies are opting for CMO services to speed up the development process and lower production costs. Thus, the importance of lyophilization in the successful delivery of biologics boosts the use of lyophilized injectables, thereby driving the market across the region.

Market Overview

The North America lyophilized injectable market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. The market's growth is attributed to growing healthcare expenditure, increasing production of generic pharmaceuticals, and growing government support to enhance pharmaceutical and biopharmaceutical industries. In addition, the growing incidence of chronic and acute diseases has led to the growth of the market indirectly. The supportive environment backs the development and commercialization of pharmaceutical and biopharmaceutical products. As per the International Trade Administration (ITA), the US is the biggest biopharmaceutical market, accounting for about a third of the global market, and is the dominant country in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), the US firms conduct over half the world's R&D in pharmaceuticals (US$ 75 billion) and hold the intellectual property rights on most new medicines. Market players are adopting strategies such as partnerships, collaborations, and mergers & acquisitions to expand the market. For instance, in August 2022, Curia announced that it had completed the transaction to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California. Similarly, in October 2020, Credence MedSystems and SCHOTT AG collaborated on the application of Credence Companion technology with SCHOTT's pre-fillable syriQ glass and SCHOTT TOPPAC polymer syringe systems. The two companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for the delivery of injectable medications via prefilled syringes. Thus, the growing pharmaceutical and biopharmaceutical industries has broadened the market's growth opportunities. The changing health conditions and requirements are the factors that continually demand newer products.

North America Lyophilized Injectable Market Revenue and Forecast to 2028 (US$ Million)

North America Lyophilized Injectable Market Segmentation

The North America lyophilized injectable market is segmented based on type of packaging, type of delivery, indication, end user, and country.

Based on type of packaging, the North America lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held the largest market share in 2022. Based on type of delivery, the North America lyophilized injectable market is segmented into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held the largest market share in 2022. Based on indication, the North America lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held the largest market share in 2022. Based on end user, the North America lyophilized injectable market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held the largest market share in 2022. Based on country, the North America lyophilized injectable market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

Aristopharma Ltd.; Baxter; CordenPharma International; Credence MedSystems, Inc.; Curia Global, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma are among the leading companies operating in the North America lyophilized injectable market.

At 5.9% CAGR, the North America Lyophilized Injectable Market is speculated to be worth US$ 1,612.66 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the North America lyophilized injectable market was valued at US$ 1,145.21 million in 2022 and is expected to reach US$ 1,612.66 million by 2028, registering a CAGR of 5.9% from 2022 to 2028. Increasing demand for contract research manufacturing services and increasing demand of biologics are the critical factors attributed to the market expansion.

Freeze drying, or lyophilization, is a drying process that consists of the sublimation of ice crystals into vapor. Lyophilization is a process based on negative temperatures, the product's activity, and stability, along with active ingredients are better retained while limiting any damage to the product and avoiding any degradation of the molecules. Thus, freeze-drying is especially popular in the pharmaceutical & diagnostic sectors. The increased quality and extended shelf life of lyophilized injectable drugs created growth opportunities for manufacturers to implement the lyophilization process in product manufacturing. The contract manufacturing and research services are in huge demand, delivering lyophilized injectable drugs to offer high-quality products to the end users. Moreover, many pharmaceutical companies are refocusing on their core capabilities such as research and development, leading to divestments of in-house manufacturing capacities, which is growing the demand of contract research manufacturing services (CRAMs) for manufacturing. Furthermore, CRAMs play crucial roles in providing additional capacities to mitigate the risk of supply shortages by offering additional sites for pharmaceutical companies with multisite supply strategies and backup capacities. Furthermore, the advantages offered by the lyophilized injectables, such as safe transit and extended pharmaceutical storage life, increased the adoption of the lyophilization technique by many enterprises across the region.

On the contrary, growing rate of product recalls hurdles the growth of North America lyophilized injectable market.

Based on type of packaging, the North America lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held 48.0% market share in 2022, amassing US$ 549.79 million. It is projected to garner US$ 767.16 million by 2028 to expand at 5.7% CAGR during 2022–2028. Based on type of delivery, the North America lyophilized injectable market is segmented into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held 43.3% market share in 2022, amassing US$ 495.97 million. It is projected to garner US$ 718.30 million by 2028 to expand at 6.4% CAGR during 2022–2028. Based on indication, the North America lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held 45.6% market share in 2022, amassing US$ 522.38 million. It is projected to garner US$ 752.16 million by 2028 to expand at 6.3% CAGR during 2022–2028. Based on end user, the North America lyophilized injectable market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held 48.1% market share in 2022, amassing US$ 550.53 million. It is projected to garner US$ 781.11 million by 2028 to expand at 6.0% CAGR during 2022–2028. Based on country, the North America lyophilized injectable market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 85.0% market share in 2022. It was assessed at US$ 973.06 million in 2022 and is likely to hit US$ 1,389.09 million by 2028, exhibiting a CAGR of 6.1% during the forecast period.

Key players dominating the North America lyophilized injectable market are Aristopharma Ltd.; Baxter; CordenPharma International; Credence MedSystems, Inc.; Curia Global, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma among others.

In April 2022, Recipharm acquires advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics. The acquisitions reflect Recipharm’s strategy of building its presence in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs (advanced therapy medicinal products). The acquisitions also enable Recipharm to establish a robust base in the US, with facilities in Boxborough, MA, and provide a platform from which to build its capabilities in new biologics modalities.

In March 2021, Baxter International Inc. and Moderna, Inc. announced that they have entered into an agreement for Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Lyophilized Injectable Market – By Type of Packaging

1.3.2 North America Lyophilized Injectable Market – By Type of Delivery

1.3.3 North America Lyophilized Injectable Market – By Indication

1.3.4 North America Lyophilized Injectable Market – By End User

1.3.5 North America Lyophilized Injectable Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Lyophilized Injectable Market – Market Landscape

4.1 Overview

4.2 North America PEST Analysis

4.3 Experts Opinion

5. North America Lyophilized Injectable Market– Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Demand for Contract Research Manufacturing Services

5.1.2 Increasing Demand of Biologics

5.2 Market Restraints

5.2.1 Product Recalls

5.3 Market Opportunities

5.3.1 Expansion of Pipeline of Lyophilized Injectable Drugs

5.4 Future Trends

5.4.1 Advancement in Lyophilized Packaging

5.5 Impact Analysis

6. Lyophilized Injectable Market– North America Analysis

6.1 North America Lyophilized Injectable Market Revenue Forecast and Analysis

7. North America Lyophilized Injectable Market Analysis – By Type of Packaging

7.1 Overview

7.2 North America Lyophilized Injectable Market Revenue Share, by Type of Packaging (2021 and 2028)

7.3 Single-use vials

7.3.1 Overview

7.3.2 Single-use vials: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Point-of-Care Reconstitution

7.4.1 Overview

7.4.2 Point-of-Care Reconstitution: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Specialty Packaging

7.5.1 Overview

7.5.2 Specialty Packaging: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

8. North America Lyophilized Injectable Market Analysis – By Type of Delivery

8.1 Overview

8.2 North America Lyophilized Injectable Market Revenue Share, by Type of Delivery (2021 and 2028)

8.3 Prefilled Diluent Syringes

8.3.1 Overview

8.3.2 Prefilled Diluent Syringes: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Single Step Devices

8.4.1 Overview

8.4.2 Single Step Devices: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Proprietary Reconstitution Devices

8.5.1 Overview

8.5.2 Proprietary Reconstitution Devices: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Multi-Step Devices

8.6.1 Overview

8.6.2 Multi-Step Devices: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Lyophilized Injectable Market Analysis – By Indication

9.1 Overview

9.2 North America Lyophilized Injectable Market Revenue Share, by Indication (2021 and 2028)

9.3 Metabolic and Oncology Conditions

9.3.1 Overview

9.3.2 Metabolic and Oncology Conditions: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Infectious Diseases

9.4.1 Overview

9.4.2 Infectious Diseases: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Autoimmune Diseases

9.5.1 Overview

9.5.2 Autoimmune Diseases: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Other Indications

9.6.1 Overview

9.6.2 Other Indications: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Lyophilized Injectable Market Analysis – By End User

10.1 Overview

10.2 North America Lyophilized Injectable Market, by End User, 2021 and 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Ambulatory Surgical Centers

10.4.1 Overview

10.4.2 Ambulatory Surgical Centers: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

10.5 Specialty Clinics

10.5.1 Overview

10.5.2 Specialty Clinics: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

10.6 Other End Users

10.6.1 Overview

10.6.2 Other End Users: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11. North America Lyophilized Injectable Market – Country Analysis

11.1 Overview

11.1.1 North America: Lyophilized Injectable Market, by Country, 2021 & 2028 (%)

11.1.1.1 US: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 US: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3 US: Lyophilized Injectable Market, by Type of Packaging, 2019–2028 (US$ Million)

11.1.1.1.4 US: Lyophilized Injectable Market, by Type of Delivery, 2019–2028 (US$ Million)

11.1.1.1.5 US: Lyophilized Injectable Market, by Indication, 2019–2028 (US$ Million)

11.1.1.1.6 US: Lyophilized Injectable Market, by End User, 2019–2028 (US$ Million)

11.1.1.2 Canada: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Canada: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.3 Canada: Lyophilized Injectable Market, by Type of Packaging, 2019–2028 (US$ Million)

11.1.1.2.4 Canada: Lyophilized Injectable Market, by Type of Delivery, 2019–2028 (US$ Million)

11.1.1.2.5 Canada: Lyophilized Injectable Market, by Indication, 2019–2028 (US$ Million)

11.1.1.2.6 Canada: Lyophilized Injectable Market, by End User, 2019–2028 (US$ Million)

11.1.1.3 Mexico: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 Mexico: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.3 Mexico: Lyophilized Injectable Market, by Type of Packaging, 2019–2028 (US$ Million)

11.1.1.3.4 Mexico: Lyophilized Injectable Market, by Type of Delivery, 2019–2028 (US$ Million)

11.1.1.3.5 Mexico: Lyophilized Injectable Market, by Indication, 2019–2028 (US$ Million)

11.1.1.3.6 Mexico: Lyophilized Injectable Market, by End User, 2019–2028 (US$ Million)

12. Industry Landscape

12.1 Overview

12.2 Inorganic Growth Strategies

12.2.1 Overview

12.3 Organic Growth Strategies

12.3.1 Overview

13. Company Profiles

13.1 Baxter

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Nipro

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Curia Global, Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Recipharm AB

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Vetter Pharma

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Jubilant HollisterStier (Jubilant Pharma Limited)

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Aristopharma Ltd.

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 CordenPharma International

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Credence MedSystems, Inc.

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 S.G. Biopharm Pvt. Ltd.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

Table 1.             North America Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Table 2.             US Lyophilized Injectable Market, by Type of Packaging – Revenue and Forecast to 2028 (US$ Million)

Table 3.             US Lyophilized Injectable Market, by Type of Delivery – Revenue and Forecast to 2028 (US$ Million)

Table 4.             US Lyophilized Injectable Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 5.             US Lyophilized Injectable Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Canada: Lyophilized Injectable Market, by Type of Packaging – Revenue and Forecast to 2028 (US$ Million)

Table 7.             Canada: Lyophilized Injectable Market, by Type of Delivery – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Canada: Lyophilized Injectable Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Canada: Lyophilized Injectable Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Mexico: Lyophilized Injectable Market, by Type of Packaging – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Mexico: Lyophilized Injectable Market, by Type of Delivery – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Mexico: Lyophilized Injectable Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Mexico: Lyophilized Injectable Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Recent Inorganic Growth Strategies

Table 15.          Recent Organic Growth Strategies

Table 16.          Glossary of Terms

Figure 1.           North America Lyophilized Injectable Market Segmentation

Figure 2.           North America Lyophilized Injectable Market – By Country

Figure 3.           North America Lyophilized Injectable Market Overview

Figure 4.           North America Lyophilized Injectable Market, By Type of Packaging

Figure 5.           North America Lyophilized Injectable Market, By Country

Figure 6.           North America: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           North America Lyophilized Injectable Market Impact Analysis of Drivers and Restraints

Figure 9.           North America Lyophilized Injectable Market– Revenue Forecast and Analysis

Figure 10.        North America Lyophilized Injectable Market Revenue Share, by Type of Packaging (2021 and 2028)

Figure 11.        North America Single-use vials: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        North America Point-of-Care Reconstitution: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        North America Specialty Packaging: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        North America Lyophilized Injectable Market Revenue Share, by Type of Delivery (2021 and 2028)

Figure 15.        North America Prefilled Diluent Syringes: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        North America Single Step Devices: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        North America Proprietary Reconstitution Devices: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        North America Multi-Step Devices: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        North America Lyophilized Injectable Market Revenue Share, by Indication (2021 and 2028)

Figure 20.        orth America Metabolic and Oncology Conditions: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        North America Infectious Diseases: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        North America Autoimmune Diseases: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        North America Other Indications: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        North America Lyophilized Injectable Market, by End User, 2021 and 2028 (%)

Figure 25.        North America Hospitals: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        North America Ambulatory Surgical Centers: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        North America Specialty Clinics: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.        North America Other End Users: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        North America: Lyophilized Injectable Market, by Key Country – Revenue (2021) (US$ Million)

Figure 30.        North America: Lyophilized Injectable Market, by Country, 2021 & 2028 (%)

Figure 31.        US: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        Canada: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33.          Mexico: Lyophilized Injectable Market – Revenue and Forecast to 2028 (US$ Million)

● Aristopharma Ltd.

● Baxter

● CordenPharma International

● Credence MedSystems, Inc.

● Curia Global, Inc.

● Jubilant HollisterStier (Jubilant Pharma Limited)

● Nipro

● Recipharm AB

● S.G. Biopharm Pvt. Ltd.

● Vetter Pharma

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America lyophilized injectable market.

● Highlights key business priorities to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the North America lyophilized injectable market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the lyophilized injectable market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

TOP